Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1- Mechanism of Action, H2 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —The purpose of this MRH research study titled “Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review, H2 2019” is to enlighten the readers about the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1with a stern focus on the development trends and opportunities projected for future years. In short, this assessment drops light on the market size and revenue share which are motivated by numerous market drivers, together with a clear insight about challenges that might create a blockage for the development of Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1

Get Sample Copy@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519486

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 – Pipeline Review, H2 2019

Summary

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 20 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 – Pipeline Review, H2 2019, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) – Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3 and 7 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Myelodysplastic Syndrome, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer, Hematological Tumor, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Non-Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), T-Cell Lymphomas and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

– The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
– The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects
– The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics

Request TOC of the Report @ https://www.marketresearchhub.com/report/induced-myeloid-leukemia-cell-differentiation-protein-mcl-1-pipeline-review-h2-2019-report.html

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) – Overview
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) – Companies Involved in Therapeutics Development
AbbVie Inc
Aileron Therapeutics Inc
Amgen Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Canget BioTekpharma LLC
Circle Pharma Inc
Complix NV
InteRNA Technologies BV
Les Laboratoires Servier SAS
Pfizer Inc
X-Rx Inc
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) – Drug Profiles
AMG-176 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-397 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5991 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-1B3 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit MCL-1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-63845 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-64315 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Breast Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL-1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Multiple Myeloma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MCL1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MCL1 and BCL1 for Solid Tumors and Liquid Tumors – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MCL1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MCL1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Enquire about This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519486

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick